Abzena and BioXpress Therapeutics partner to provide global biosimilar support

The combined capabilities will offer flexibility and innovation from small-scale biosimilar development through to large-scale manufacturing

The partnership creates an integrated solution between two service providers with expertise in biosimilar development and good manufacturing practice (GMP), allowing for a simplified drug development timelines for the biosimilars market.

Furthermore, the combined expertise will provide a flexible and innovative approach from small-scale biosimilar development through to large-scale manufacturing.

Biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy, cell line and process development, through to clinical and commercial GMP manufacture.

According to Abzena's CEO, Jonathan Goldman, the combined services will provide customers with a "de-risked approach" to biosimilar development, through to clinical development and ultimately to the market.”